Loading organizations...

§ Private Profile · San Diego, CA, USA
A biotechnology company developing ultra-safe therapies for weight management, obesity, and related metabolic disorders.
Elcelyx Therapeutics was a San Diego, California-based biotechnology company that developed specialized therapies for weight management, obesity, and metabolic disorders such as Type 2 diabetes. The firm focused on creating treatments designed to improve glucose metabolism without systemic side effects, advancing lead clinical candidates including Lovidia and NewMet. During its operational tenure, the enterprise secured significant venture capital backing, including a $40 million Series E financing round and an additional $5.8 million to prepare for Phase III clinical trials. The company's early development efforts were supported by prominent institutional investors such as Morgenthaler Ventures, Kleiner Perkins Caufield & Byers, and Technology Partners. Despite advancing its clinical pipeline, the privately held business ultimately ceased its operations and was officially listed as out of business in September 2021. Elcelyx Therapeutics was founded in 2010 by Alain Baron.
Elcelyx Therapeutics has raised $90.2M across 5 funding rounds.
Elcelyx Therapeutics has raised $90.2M in total across 5 funding rounds.
Elcelyx Therapeutics is a biotechnology company developing therapeutic agents that modulate the gut's neuro-enteroendocrine system, particularly L-cells, to amplify hormone release for glucose regulation and metabolic disorders.[1][2][3] Its lead product, Metformin DR (NewMet), delivers metformin directly to the lower gut to improve tolerability for Type 2 diabetes patients who experience side effects from standard formulations, targeting unmet needs in oral anti-diabetics with reduced systemic bioavailability.[1][2][3] Additional candidates like Lovidia address weight management and obesity by leveraging Gut Sensory Modulation (GSM) technology for safer, localized effects without broad side effects.[4] Backed by $96.9 million in funding, the company serves patients with diabetes, prediabetes, and obesity, showing early clinical momentum through Phase 2b trials for NewMet.[3][4]
Headquartered in San Diego with a small team of about 9 employees, Elcelyx focuses on repositioning existing drugs via its GSM platform for rapid market entry in high-need areas like metabolic health.[2][3]
Elcelyx Therapeutics was founded in 2010 by Alain Baron, who serves as President and CEO, building on the discovery of gut enteroendocrine cell modulation—specifically L-cells in the lower gut—for systemic effects on glucose and metabolism.[1][2][3] The idea emerged from scientific insights into nutrient sensing and GSM technology, enabling safer therapies by targeting the gut locally rather than systemically.[2][4] Venture-backed from inception, it raised funds across Series B to E rounds from investors like Morgenthaler Ventures, GSM Fund, and Clough Capital, totaling nearly $97 million by 2015, including a $40 million Series E.[3][4]
Early traction included advancing Metformin DR to Phase 2b for Type 2 diabetes and Lovidia for weight loss, with a pivotal 2013 spin-off of non-NewMet assets into NaZura BioHealth to streamline focus.[2] This nimble evolution under Baron's leadership, drawing from prior biotech experience, positioned Elcelyx for blockbuster potential in diabetes and obesity markets.[1][2]
Elcelyx stands out in biotech through its proprietary Gut Sensory Modulation (GSM) platform, which targets the lower gut's L-cells for hormone release (e.g., GLP-1 agonists for glucose control) without systemic exposure, minimizing side effects like GI distress common in traditional therapies.[1][2][4]
Key strengths include:
Elcelyx rides the explosive growth in metabolic therapies, fueled by rising obesity and diabetes rates, where gut-brain axis modulation aligns with trends in GLP-1 drugs (e.g., Ozempic) but offers oral, lower-risk alternatives.[1][4] Timing is ideal amid demands for tolerable, non-injectable options—its GSM platform influences biotech by pioneering enteroendocrine targeting, potentially reshaping Type 2 diabetes treatment for 30-50% of patients intolerant to standard metformin.[3]
Market forces like aging populations and post-pandemic metabolic health focus favor Elcelyx, while its VC model accelerates small-biotech innovation in a capital-intensive field.[2][4] By spinning assets and prioritizing Phase 2b assets, it contributes to ecosystem efficiency, bridging academic gut-sensing research to commercial viability.
Elcelyx's GSM platform positions it for partnerships or acquisition by big pharma seeking differentiated diabetes/obesity assets, especially if Phase 2b data for NewMet validates superior tolerability.[1][2] Next steps likely include trial readouts, expanded indications (prediabetes), or licensing deals amid GLP-1 market saturation. Trends like AI-driven drug repurposing and oral peptide mimics will amplify its edge, potentially evolving it from nimble developer to key player in $100B+ metabolic space—delivering on its promise of safety-first therapies from gut insight to patient impact.[3][4]
Elcelyx Therapeutics has raised $90.2M in total across 5 funding rounds.
Elcelyx Therapeutics's investors include James Xiaodong Liu, Advanced Technology Ventures, Longwood Fund, Morgenthaler Ventures, The Column Group, GSM Fund, Kleiner Perkins, Technology Partners, Ralph "Chris" Christoffersen, Alain D. Baron.
Elcelyx Therapeutics has raised $90.2M across 5 funding rounds. Most recently, it raised $40.0M Series E in September 2015.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 1, 2015 | $40M Series E | James Xiaodong LIU | Advanced Technology Ventures, Longwood Fund, Morgenthaler Ventures, The Column Group, GSM Fund, Kleiner Perkins, Morgenthaler Ventures, Technology Partners | Announced |
| Feb 1, 2014 | $25M Series C | — | Advanced Technology Ventures, Longwood Fund, Morgenthaler Ventures, The Column Group | Announced |
| Feb 14, 2013 | $20M Series C | GSM Fund | Kleiner Perkins, Morgenthaler Ventures, Technology Partners | Announced |
| Aug 1, 2012 | $4M Series B | — | Advanced Technology Ventures, Longwood Fund, Morgenthaler Ventures, The Column Group, Kleiner Perkins, Ralph "Chris" Christoffersen, Technology Partners | Announced |
| Mar 19, 2010 | $1.2M Venture Round | Alain D. Baron | — | Announced |